Zealand Pharma: Hypoglycemia trials

The registry lists 11 Hypoglycemia studies with Zealand Pharma as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 2Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1DCompletedNCT05378672Phase 3Results posted
• Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DMCompletedNCT03688711Phase 3Results posted
• Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM ChildrenCompletedNCT03667053Phase 3Results posted
• A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes SubjectsCompletedNCT03378635Phase 3Results posted
• A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes MellitusCompletedNCT03216226Phase 3Results posted
• Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated AdultsWithdrawnNCT04824872Phase 2
• A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DMCompletedNCT03895697Phase 3
• Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV AdministrationCompletedNCT03735225Phase 1
• Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed GlucagonCompletedNCT02660008Phase 2
• Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207CompletedNCT02390141Phase 1
• Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a ComparatorCompletedNCT02367053Phase 1